Updated March 18, 2013

 January 2013

• Endometrial cells in Pap tests—when are they significant?
• Screening and dotting digital/virtual slides: A new challenge
• New year, new online program: Pap Education Digital
• Touch Imprint/Crush Preparation—a new SAM course

 August 2012

• New screening guidelines—order amid complexity
• My life as glass
• For violations found in inspections, what are appropriate corrective actions?

 May 2012

• Cytopathology of pulmonary infections
• Excluding specimens from cytologic review
• Can we protect our images in a digital world?
• A webinar on regs, surveys, deficiencies

 January 2012

• Case numbers: How few are too few? When do you lose skills?
• Approved assays for detecting HPV DNA—design, indications, and validation
• Critical values and diagnoses, with emphasis on cytopathology
• Fields of View online—what it is, how it works
• Thanks for your donations

 August 2011

• Ultrasound in the FNA clinic—how to get started
• Anal cancer screening
• Your Pap and nongyn program suggestions
• In mandated cytology PT, fatal flaws remain
• Wanted: nongynecologic slides from participating labs

 May 2011

• Use of cytology and small biopsy specimens in diagnosing, treating lung cancer
• Validating and verifying molecular tests in cytopathology
• Similarities, differences between anal and cervical cancer screening
• Getting to know us

January 2011

• Digital cytopathology and telecytology: a method coming of age
• Machine? Medical director? What to put in cytology reports
• Imaging systems, workload limits, and screening accuracy
• New this year: Fields of View education course
• In the mail—Pap supplemental questionnaire
• Regionalizing education, fellowship training, and more

 August 2010

• Two new checklist questions, changes to others
• Licensure—status in the states and scope of practice
• Benchmarking data for laboratory use in QA
• Survey of gynecologic cytopathology practices set to begin

 May 2010

• Views from on top: A look at the Future of Cytopathology Summit
• Complying with cross-contamination question
• Q & A
• ACOG bulletin on cervical cytology screening
• Your questions about feedback, faxback, staining, and more
• Soon, a survey of gyn cytopathology practices

 January 2010

• New FDA approvals of HPV vaccines
• Guidelines for reporting nongyn cytology specimens
• What to do with contaminated cytospin machine
• New FNA glass slide program
• See rare and unusual cases, and earn CME online
• Anatomic pathology programs—changes for 2010
• Discovering best practices in gyn cytopathology
• For CAP HPV Survey, choose your media type

 August 2009

• To Baghdad and back
• Getting the word out about the ’06 guidelines
• New guidance on HPV DNA test use
• Unsatisfactory Pap reporting rates
• In Cusco, Peru, Pap tests for 1,200 women
• For nongyn program, ancillary images online
• With Cervista HPV 16/18 approval, now a genotyping algorithm
• SurePath media challenges to be reformulated

 May 2009

• FocalPoint GS Imaging passes the test
• HPV testing—what and how labs did in ’08
• PT performance of HSV, Candida challenges
• The following was sent to the New York Times
• In the news, low-tech loses to high-tech
• On cytology PT, CAP enlightens CMS
• For nongyn program, ancillary images online

 January 2009

• Cytology PT: where we are, where to now
• This year, an enhanced nongynecologic program
• Recommended Reading
• PAP/NGC Q and A
• CAP HPV Survey meets CLIA requirement
• Please, donate your Pap slides

 August 2008

• Decade of wisdom on ultrasound-guided FNAs
• For all of us, a place to ponder cytopathology’s future
• Practice patterns in HPV testing
• PAP/NGC Q and A
• Heads in the sand—or not?
• For cytotechnologists, molecular training a must
• Cytotechnology schools under threat

 May 2008

• A dialogue on thyroid disease reporting and management
• Cervical cancer screening guidelines —communicating the right message
  • Soon, a new gynecologic cytology atlas
  • Statistically speaking, federally mandated PT is unreliable
• Gyn cytology PT–’06 results and tough questions

 February 2008

• Cervical cancer screening’s future in the post-vaccination era—a viewpoint
• Perilous times for the Pap test?
• PAP/NGC Q and A
• Always inspection-ready
• CAP HPV Survey to begin soon

 November 2007

• How to create a database form for educational slide file sets
• Educational cases online twice a year
• FNA or core needle biopsy? Why not both?
• FNA and the Universal Protocol
• ASCCP ’06 consensus guidelines—what’s new and different?
• Non-small cell lung cancer in the targetedtherapy era
• Routine endometrial sampling of asymptomatic premenopausal women shedding normal endometrial cells in Pap tests is not cost-effective

May 2007

• What is the role of fine needle aspiration in evaluating thyroid nodules?
• Pap PT appeals—how the process works
• Queries and Comments

January 2007

• “Retrophobia” and the 5-year retrospective review
• Online: gynecologic and nongyn educational programs
• Reality check for POC testing—making it work
• Give and you shall receive
• Vaccines for prevening cervical cancer—where we are now
• Understanding HPV testing’s place in primary screening
• A digital slide program in FNAs
• Share your ’06 cervical cytology statistics
• Enrollment tips for ’07 Pap PT
• ASC-H: HPV data and histologic outcomes

September 2006

• Categorizing anal-rectal cytology challenges
• View rare cases, earn CME credits online
• When and how to use CPT code 88172
• An e-learning course for cytoprep staff
• Your oft-asked quections about CAP Pap proficiency testing
• Q & A
• It’s time to renew your Pap PT
• Please tell it like it is
• A tale of two tests: cytology gyn screening and mammography

May 2006

• 2006 regulatory PT results: Waht do they really mean?
• Are you seeing what’s there?
• Back to the beginning of the CET Consortium
• Significance of benign endometrial cells in cervicovaginal smears
• On CAP’s Web site, so much at your fingertips
• Nongyn cytopathology—more to the program than you might think

February 2006

• A difficult distinction
• The debate over how to report nongynecologic cytology
• Molecular testing in cytopathology: Where are we, where do we go from here?
• How the CAP’s PT program works
• Confusion about errors in anatomic pathology: problems with categorizing and reporting
• Q & A

October 2005

• HPV vaccines—trying to fill the Pap gap
• Proficiency testing and CME in one program
• Proficiency testing: A Winkle in time
• YESRs—where and why they’re available
• Recommended reading: Distinguishing carcinoid tumor from small cell carcinoma of the lung
• Q & A

June 2005

• Billing and coding in cytopathology: Deciphering the alphanumeric soup
• Measuring the significance of field validation in the CAP Interlaboratory Comparison Program: How good are the experts?
• Performance of SurePath liquid-based cytology
• Pitfalls in salivary gland fine-needle aspiration cytology
• Using liquid-based cervical cytology specimens to test for Chlamydia
• Fine-needle aspiration of pulmonary hamartoma
• Cytopathology at CAP ’05
• We need a few good slides
• Cytotechnology
• Q & A

January 2005

• Needle points: The lab’s role in endoscopic ultrasound-guided FNA
• The upsides and downsides of state licensure for cytotechnologists
• Recommended Reading
• Removing dots from cytology slides—liability issues